Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?

Detalles Bibliográficos
Autores principales: Yamazaki, Shinji, Evers, Raymond, De Zwart, Loeckie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835114/
https://www.ncbi.nlm.nih.gov/pubmed/36369633
http://dx.doi.org/10.1002/psp4.12879
_version_ 1784868604837101568
author Yamazaki, Shinji
Evers, Raymond
De Zwart, Loeckie
author_facet Yamazaki, Shinji
Evers, Raymond
De Zwart, Loeckie
author_sort Yamazaki, Shinji
collection PubMed
description
format Online
Article
Text
id pubmed-9835114
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98351142023-01-17 Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis? Yamazaki, Shinji Evers, Raymond De Zwart, Loeckie CPT Pharmacometrics Syst Pharmacol Perspectives John Wiley and Sons Inc. 2022-11-11 /pmc/articles/PMC9835114/ /pubmed/36369633 http://dx.doi.org/10.1002/psp4.12879 Text en © 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Perspectives
Yamazaki, Shinji
Evers, Raymond
De Zwart, Loeckie
Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
title Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
title_full Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
title_fullStr Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
title_full_unstemmed Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
title_short Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
title_sort physiologically‐based pharmacokinetic modeling for primary metabolites of cyp3a and p‐glycoprotein inhibitors in drug–drug interactions: should we assume the free drug hypothesis?
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835114/
https://www.ncbi.nlm.nih.gov/pubmed/36369633
http://dx.doi.org/10.1002/psp4.12879
work_keys_str_mv AT yamazakishinji physiologicallybasedpharmacokineticmodelingforprimarymetabolitesofcyp3aandpglycoproteininhibitorsindrugdruginteractionsshouldweassumethefreedrughypothesis
AT eversraymond physiologicallybasedpharmacokineticmodelingforprimarymetabolitesofcyp3aandpglycoproteininhibitorsindrugdruginteractionsshouldweassumethefreedrughypothesis
AT dezwartloeckie physiologicallybasedpharmacokineticmodelingforprimarymetabolitesofcyp3aandpglycoproteininhibitorsindrugdruginteractionsshouldweassumethefreedrughypothesis

Ejemplares similares